npj Digital Medicine· 2026Q1
The application, development and challenge of digital twin in drug evaluation
- 0citations
- Q1SCImago
- 2026year
Short summary
Digital twins (DT) can now integrate multi-omics data using hybrid models for personalized patient simulations, enabling drug evaluation and repurposing.
AI-generated from the title and abstract; the full text is not read.
Key points
- Digital twins can integrate multi-omics data via hybrid models for personalized patient simulations.
- DT applications are now possible in drug evaluation and drug repurposing discovery.
- Practical and regulatory issues have emerged alongside DT advancements.
- A staged development roadmap and solutions to pivotal challenges are proposed.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract With the improvement of computational resources and development of artificial intelligence, current digital twins (DT) can achieve the integration of multi-omics data via hybrid mechanism- and data-driven models, thereby enabling personalized simulation of patients, organs, and cells. This makes the application of DT in drug evaluation and drug repurposing discovery possible. However, in the rapidly developing situation, practical and regulatory issues have also emerged. We review current and emerging applications of DT across the drug evaluation continuum and proposed a staged development roadmap. We also further highlight pivotal challenges that must be addressed to realize the full potential of DT in drug evaluation.
The authors' abstract, as published at the source. npj Digital Medicine, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Industrial and Manufacturing Engineering
Industrial and Manufacturing EngineeringEngineering